公开(公告)号：WO2023039662A1

公开(公告)日：2023-03-23

申请号：PCT/CA2022/051362

申请日：2022-09-13

Applicant: UNIVERSITY OF OTTAWA ,  SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES ,  THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING / MCGILL UNIVERSITY

Inventor： SUN, Jim Jian ,  YANG, Weibo ,  XU, Zhongliang ,  CHEN, Lu ,  LIANG, Yi Chu ,  LUPIEN, Andréanne

IPC: C07D221/06 ,  A61K31/473 ,  A61K31/4741 ,  A61P31/04 ,  A61P31/06 ,  C07D401/04 ,  C07D401/12 ,  C07D403/06 ,  C07D405/12 ,  C07D417/04 ,  C07D471/04 ,  C07D491/056 ,  C07D491/153

Abstract: The present disclosure provides compounds according to Formulas I and II: where R1 to R11 independently denote: H; D; a halogen; an optionally substituted straight chain or branched alkyl group; an optionally substituted alkenyl group; an optionally substituted alkynyl group; an optionally substituted aryl group; an optionally substituted heteroaryl group; or an optionally substituted carbocyclic group. X' is a pharmaceutically- or synthetically-acceptable anion. These compounds are metal-dependent PP2C Ser/Thr phosphatase inhibitors and can be used to treat related diseases, such as infectious diseases.

公开(公告)号：WO2022007890A1

公开(公告)日：2022-01-13

申请号：PCT/CN2021/105208

申请日：2021-07-08

Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES ,  HANGZHOU LEADING EDGE PHARMACEUTICAL LTD. ,  SHANGHAI KANGQIAN BIOTECHNOLOGY LIMITED

Inventor： LUO, Cheng ,  XU, Meng ,  CHEN, Shijie ,  LI, Yilin ,  CHEN, Yantao ,  JIANG, Hualiang ,  CHEN, Kaixian ,  JIANG, Zhanpeng

IPC: A61K31/7088 ,  A61K38/55 ,  C07K16/06 ,  A61K39/00

Abstract: Provided are compositions and methods for attenuating YTHDF1 activities, as well as compositions and methods for promoting immune responses. For example, a YTH N6-Methyladenosine RNA Binding Protein 1 (YTHDF1) attenuating agent, is provided wherein said agent comprises a compound, and when bound to YTHDF1, said compound binds to at least one residue of YTHDF1.

公开(公告)号：WO2019222134A1

公开(公告)日：2019-11-21

申请号：PCT/US2019/032094

申请日：2019-05-14

Applicant: BAYLOR COLLEGE OF MEDICINE ,  VAN ANDEL RESEARCH INSTITUTE ,  SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Inventor： TSAI, Ming-Jer ,  TSAI, Sophia Y. ,  CHENG, Chiang-Min ,  WANG, Leiming ,  XU, Huaqiang Eric ,  SHI, Jingjing ,  GONG, Wanchun ,  YOU, Erli

IPC: A61K31/13 ,  A61K31/425 ,  A61K31/426 ,  C07D277/02 ,  C07D277/20 ,  C07D277/52

Abstract: The invention relates in one aspect to the identification of compounds that inhibit COUP-TFII activity. In certain embodiments, the compounds of the invention have submicromolar activity against COUP-TFII. In other embodiments, the compounds of the invention have no measurable effect on COUP-TFII-negative cells. In yet other embodiments, the compounds of the invention inhibiting prostate tumor growth in a subject without significant effect on the subject's body weight.

公开(公告)号：WO2021217740A1

公开(公告)日：2021-11-04

申请号：PCT/CN2020/090572

申请日：2020-05-15

Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Inventor： LUO, Cheng ,  ZHANG, Hao ,  XU, Heng ,  CHEN, Kaixian ,  JIANG, Hualiang

IPC: A61K31/405 ,  A61P11/00 ,  A61P31/14

Abstract: Provided herein is a method for preventing, treating and/or ameliorating a Coronaviridae infection in a subject in need thereof, comprising administering an effective amount of a compound that is fluvastatin, a prodrug, a metabolite, or a derivative thereof, or a pharmaceutically acceptable salt or ester of any of the foregoing. And fluvastatin could lower the virus load in patients infected with the SARS-CoV-2 significantly.

公开(公告)号：WO2017133663A1

公开(公告)日：2017-08-10

申请号：PCT/CN2017/072828

申请日：2017-02-03

Applicant: SHANGHAI FOCHON PHARMACEUTICAL CO., LTD. ,  SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES ,  CHONGQING FOCHON PHARMACEUTICAL CO., LTD.

Inventor： GENG, Meiyu ,  DING, Jian ,  AI, Jing ,  PENG, Xia ,  YU, Chuiliang ,  ZHAO, Xingdong ,  RONG, Yue ,  LIU, Hongbin ,  CHEN, Zhifang ,  TAN, Rui ,  YANG, Lijun ,  WANG, Xianlong ,  LIU, Qihong ,  LI, Zhifu ,  ZHANG, Weipeng ,  SUN, Jing ,  WANG, Weibo

IPC: C07D405/14 ,  A61K31/558 ,  A61P35/00

CPC classification number: C07F9/5325

Abstract: Provided are certain ALK inhibitors, pharmaceutical compositions thereof, and methods of use thereof.

Abstract translation: 提供某些ALK抑制剂，其药物组合物及其使用方法。

公开(公告)号：WO2017066014A1

公开(公告)日：2017-04-20

申请号：PCT/US2016/055096

申请日：2016-10-03

Applicant: SUNNYLIFE PHARMA INC. ,  SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Inventor： LIAO, Xibin ,  LI, Jia ,  LU, Zhijian ,  ZHOU, Yubo ,  GAO, Anhui

IPC: C07D401/14 ,  A61K31/506

CPC classification number: C07D487/04 ,  C07D471/04

Abstract: Bruton's tyrosine kinase (Btk) inhibitors have the following Formula (I):

Abstract translation: 布鲁顿氏酪氨酸激酶（Btk）抑制剂具有下式（I）：

公开(公告)号：WO2015048316A1

公开(公告)日：2015-04-02

申请号：PCT/US2014/057497

申请日：2014-09-25

Applicant: VAN ANDEL RESEARCH INSTITUTE ,  SHANGHAI INSTITUTE OF MATERIA MEDICA

Inventor： XU, Huaqiang, Eric ,  HE, Yuanzheng ,  MELCHER, Karsten ,  WEI, Yi ,  JINGJING, Shi

IPC: A61K31/58 ,  A61P5/44 ,  A61P11/06 ,  C07J71/00

CPC classification number: C07J71/0047 ,  C07J3/005 ,  C07J5/0053

Abstract: The present invention relates to novel glucocorticoid compounds. The invention also relates to methods of using these compounds, the synthesis of these compounds, and to compositions and formulations comprising the glucocorticoid compounds, and uses thereof.

Abstract translation: 本发明涉及新型糖皮质激素化合物。 本发明还涉及使用这些化合物的方法，这些化合物的合成，以及包含糖皮质激素化合物的组合物和制剂及其用途。

公开(公告)号：WO1995018088A1

公开(公告)日：1995-07-06

申请号：PCT/JP1993001907

申请日：1993-12-27

Applicant: TAISHO PHARMACEUTICAL CO., LTD. ,  INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF MEDICAL SCIENCES ,  GUO, Zong-ru ,  HAN, Rui ,  CHU, Feng-ming ,  HE, Xiao-qing ,  XIA, Li-juan ,  KAMEO, Kazuya ,  NAKAIKE, Shiro

Inventor： TAISHO PHARMACEUTICAL CO., LTD. ,  INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF MEDICAL SCIENCES

IPC: C07C65/105

CPC classification number: C07C65/28 ,  C07C65/19

Abstract: A benzoic acid derivative represented by general formula (I) and a salt thereof wherein R and R may be the same or different from each other and each represents hydrogen or C1-C5 alkyl. The compound is superior to the conventional ones in antitumor and differentiation-inducing actions.

Abstract translation: 由通式（I）表示的苯甲酸衍生物及其盐，其中R 1和R 2可以相同或不同，各自表示氢或C 1 -C 5烷基。 该化合物在抗肿瘤和分化诱导作用中优于常规化合物。

公开(公告)号：WO2014071832A1

公开(公告)日：2014-05-15

申请号：PCT/CN2013/086571

申请日：2013-11-05

Applicant: SHANGHAI FOCHON PHARMACEUTICAL CO LTD ,  SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES

Inventor： WANG, Weibo ,  GENG, Meiyu ,  DING, Jian ,  ZHAO, Xingdong ,  AI, Jing ,  TIAN, Qiang ,  PENG, Xia ,  ZHANG, Weipeng ,  LIU, Hongbin ,  TAN, Haohan ,  CHEN, Ling

IPC: C07D405/14 ,  A61K31/558 ,  A61P35/00

CPC classification number: C07D487/04 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5377 ,  A61K45/06 ,  C07D405/12 ,  C07D405/14 ,  A61K2300/00

Abstract: Disclosed herein are ALK kinase inhibitors, pharmaceutical compositions thereof, and pharmaceutical uses thereof. More particularly disclosed herein are compounds of Formula (I), wherein each substituent of Formula (I) is defined as in the description.

Abstract translation: 本文公开了ALK激酶抑制剂，其药物组合物及其药物用途。 本文更具体公开的是式（I）的化合物，其中式（I）的每个取代基如描述中所定义。

公开(公告)号：WO2012003190A1

公开(公告)日：2012-01-05

申请号：PCT/US2011/042221

申请日：2011-06-28

Applicant: GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT ,  INSTITUTE OF MATERIA MEDICA ,  LIU, Kai ,  COOPER, Christopher, B. ,  HUANG, Haihong ,  LI, Chun ,  LIU, Binna ,  LIU, Yang ,  MA, Zhenkun ,  WANG, Jingbin ,  YIN, Dali ,  ZHANG, Dongfeng ,  ZHANG, Gang ,  ZHANG, Hao

Inventor： LIU, Kai ,  COOPER, Christopher, B. ,  HUANG, Haihong ,  LI, Chun ,  LIU, Binna ,  LIU, Yang ,  MA, Zhenkun ,  WANG, Jingbin ,  YIN, Dali ,  ZHANG, Dongfeng ,  ZHANG, Gang ,  ZHANG, Hao

IPC: C07D401/12 ,  A61P31/06 ,  A61K31/495

CPC classification number: C07D409/14 ,  A61K31/498 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/12 ,  C07D407/14 ,  C07D409/12

Abstract: The present invention relates to riminophenazines having heteroaromatic substitutions, including those with 2-heteroaryl-amino substituents, to their preparation, and to their use as drugs for treating Mycobacterium tuberculosis and other microbial infections, either alone or in combination with other anti-infective treatments.

Abstract translation: 本发明涉及具有杂芳香取代基，包括具有2-杂芳基 - 氨基取代基的那些，其制备方法及其用作治疗结核分枝杆菌和其它微生物感染的药物，其单独使用或与其它抗感染治疗组合 。